• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Evoke gets notice of allowance for additional US patent covering Gimoti metoclopramide nasal spray

According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent that will protect the company’s Gimoti metaclopramide nasal spray until 2030. The patent (No. 11628150, “Nasal Formulation of Metoclopramide”) is expected to be issued on April 18, 2023. Other patents covering Gimoti include Nos. 11,020,361 and 8,334,281, both titled “Nasal Formulations of Metoclopramide,” and No. 11,517,545, titled, “Treatment of Moderate and Severe Gastroparesis,” issued in December 2022.

Gimoti was approved by the FDA for the treatment of diabetic gastroparesis in June 2020 and in April 2022, the company was granted 3 years of market exclusivity for the nasal spray.

Evoke Pharma President and Chief Operating Officer Matt D’Onofrio commented, “The novelty of Gimoti is crucial for the work we do every day to ensure better outcomes for gastroparesis patients. We continue to develop and grow the product in the market and are pleased to fortify our patent estate once again. Aside from the clinical benefit our product provides to patients and healthcare providers, we believe the addition of this new patent signifies the value and contribution of Gimoti to the field of GI motility.”

Read the Evoke Pharma press release.

Share

published on April 10, 2023

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews